PRODUCT LITERATURE

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

---

At their recommended doses for severe RI, vildagliptin (50 mg once daily) compared with sitagliptin (25 mg once daily) demonstrated similar efficacy
and both drugs were well tolerated. This study provides further support for the use of DPP-4 inhibitors in patients with severe RI

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Vildi

Specific Detail Info

Diabetologia

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment